Table 5. Estimated budget impact in Wales, scenario analysis with dose frequency increased to every four weeks after six months treatment

	Year 1	Year 2
Scenario without infliximab - assuming treatment is with either bimekizumab or upadacitinib		
Number of patients given bimekizumab	5	10
Number of responders	3	6
Number of patients given upadacitinib	5	10
Number of responders	4	8
Scenario with infliximab – assuming displaces active comparators		
Number of patients given infliximab	10	10
Number of responders standard dose	4	8
Number of responders with dosing frequency every 4 weeks at 6 months	3	6
Estimated costs of above scenarios		
Total annual costs without infliximab	¶¶	¶¶
Total annual costs with infliximab	¶¶	¶¶
Annual net cost compared with active comparators	¶¶	¶¶
Annual net cost compared with BSC	¶¶	¶¶

BSC: best supportive care
¶¶ Commercial in confidence data removed